Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyl-CpG binding domain protein 3-like 2 (MBD3L2) is a protein-coding gene related to the methyl-CpG-binding protein family but notably lacks the methyl-CpG-binding domain required for binding methylated DNA. It is homologous to MBD2 and MBD3 and can interact with MBD3 and components of the nucleosome remodeling and histone deacetylase (NuRD) complex. MBD3L2 acts as a transcriptional repressor when tethered to DNA and may modulate the recruitment of the NuRD complex, potentially relieving or reinforcing repression depending on context. Its expression is developmentally regulated, notably enriched in germ cells and early embryos in mice, and has been detected in human germ cell tumors and select somatic tissues. While implicated in chromatin regulation and transcriptional modulation, it is not a conventional therapeutic target (receptor, enzyme, transporter, etc.), and there is currently no evidence linking it to drug interactions, biomarker utility, or specific safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyl-CpG binding domain protein 3-like 2 (MBD3L2).